EMEA-000060-PIP08-19 - paediatric investigation plan

Canakinumab
PIPHuman

Key facts

Invented name
Ilaris
Active Substance
Canakinumab
Therapeutic area
Oncology
Decision number
P/0029/2020
PIP number
EMEA-000060-PIP08-19
Pharmaceutical form(s)
  • Powder for solution for injection
  • Solution for injection
Condition(s) / indication(s)
Treatment of lung carcinoma
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 613241111

Decision type
W: decision granting a waiver in all age groups for all conditions or indications
Decision date

Decision

Share this page